ESMO 2021 | DESTINY-Gastric02: T-Dxd as a second-line treatment for HER2-positive gastric cancer

Elizabeth Smyth, MD, Cambridge University Hospitals, Cambridge, UK, summarises the rationale and results of the DESTINY-Gastric02 trial (NCT04014075). This was a non-randomised Phase II trial of trastuzumab deruxtecan (T-Dxd) as a second-line treatment for patients with HER2-positive gastric cancer. The overall response rate, which was the primary endpoint, was 38%, with a duration of response of more than 8 months. The treatment was well-tolerated and encouraging results were achieved. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.